Evidence-Based Nutrition For Chronic Disease Prevention

Erythritol: Heart Attack in a Packet? A Review of the Science.

Published on 11/21/2026

In 2023, headlines claimed that the sweetener erythritol was linked to heart attacks and strokes. In 2025, more headlines said it could harm your brain. And erythritol is everywhere these days, hiding in your “keto” ice cream, your protein bars, or your zero-sugar energy drink.

So, should you panic and toss it all? Or is this another case of overblown, misleading headlines?  

As usual, these headlines oversimplify the science. By the end of this post, you’ll understand what the science does – and does not – say about what erythritol might be doing to your heart and brain, so that you can decide whether you want to consume erythritol or not.

What is Erythritol?

If you have a sweet tooth and are trying to cut back on added sugar, you may be excited about all of the so-called “natural” sweetener options on the market today. Erythritol is one such sugar alternative that has become ubiquitous in keto and sugar-free foods. Erythritol is a type of sugar alcohol, meaning its chemical structure is similar to that of both a sugar molecule and an alcohol molecule. Other sugar alcohols you may have heard about include xylitol, sorbitol, and mannitol. Erythritol became popular because it is essentially calorie-free and doesn’t raise your blood sugar or insulin, but unlike artificial sweeteners or stevia, it tastes and feels very similar to sugar, with no bitter aftertaste. Also, unlike some other sugar alcohols (e.g., xylitol), it is better tolerated in the gut.

But here’s the problem with calling erythritol a “natural” sweetener. It’s natural in the sense that it IS found in some foods, like grapes, pears, melon, mushrooms, and fermented beverages, like wine and sake. But the amounts found naturally in foods are minuscule, whereas the stuff in the packets or processed foods at the supermarket is made by fermenting corn, glucose, or sucrose and is concentrated up to a thousand times what you’d ever find in nature. Given that pears, for example, have about 40 mg/kg of erythritol, you’d have to eat around 100 kilograms of pears to get one teaspoon of erythritol naturally. So the real question we are asking here is: what happens when we eat a lot of something we previously consumed only in minuscule amounts?

Amount of pears we need to eat to consume one teaspoon of erythritol.
Amount of pears we need to eat to consume one teaspoon of erythritol.

The Promise and Hope of Erythritol

Initially, other than some gastrointestinal upset at high doses, there did not appear to be any apparent downside to consuming concentrated erythritol, and it was deemed safe by the FDA in 2001. It has also been approved for use in the European Union, in 2003. Erythritol was initially seen as holding promise as a potentially health-promoting alternative to sugar. Some petri dish and animal studies suggested that erythritol might have antioxidant effects and protect endothelial cells from damage caused by chronically high blood glucose in type 2 diabetes. One uncontrolled human trial suggested that erythritol might help improve cardiovascular risk markers among people with diabetes. Notably, these were all industry-funded studies, or at least studies by authors funded by industry. But even some small, non-industry-funded controlled crossover trials hinted that erythritol might increase the hormones that signal fullness and get you to eat a bit less at your next meal. This would seem promising for weight loss, right?! 

Unfortunately, we still have zero evidence that erythritol actually helps anyone lose weight in the real world. And all those ideas that erythritol might be beneficial for health were squashed by a scary study that dropped in 2023, making us question whether erythritol was more poison than health food.

The Scare

Newspaper headlines about this study told us erythritol was linked to heart attack, stroke, and early death.

These headlines were based on a study in which researchers looked at 100s of compounds in the blood of people who did and did not experience a major cardiovascular event across a three-year period following the blood draw. They found that erythritol was one of multiple polyols that tended to be in higher concentrations in the blood of people who experienced a major cardiac event (sugar alcohols are a type of polyol chemically). Sounds scary, right? 

But let’s be clear: these findings did not come from the researchers feeding people erythritol and watching what happened over time. Instead, this was an observational study of older and fairly sick people, some of whom had a heart attack or a stroke during the follow-up period and others didn’t. The researchers used blood samples drawn at the baseline, before some people had the cardiovascular events, and tried to find new metabolites that tended to be higher or lower among those who did develop a heart attack or stroke during the follow-up years. So they didn’t start with any hypotheses about erythritol. They just wanted to identify new markers in blood that could help us identify people with a particularly high risk of having a CVD event. Erythritol was one of many compounds that tended to be higher among those who experienced such a CVD event.

That initial study was what we in science call a fishing expedition. They didn’t have any clear hypotheses about what they would find. They just had a tool we call metabolomics, which lets you measure many different metabolites in blood at once, and they tried to use it to find something interesting. So now they had found that higher erythritol concentrations in blood were more common among those who had a CVD event.

Because this could have just been chance, they now used blood samples from two similar cohorts to confirm this finding (see figure below), and indeed, they were able to replicate their initial result: people in the groups with the highest erythritol levels in blood had a higher risk of a cardiovascular event, in both cohorts. That finding seemed concerning, given that erythritol is now an ingredient used to sweeten many foods. 

Design of the study by Witkowski et al. that was the first to report an association between blood erythritol levels and cardiovascular risk.
Design of the study by Witkowski et al. that was the first to report an association between blood erythritol levels and cardiovascular risk.

But there’s an important twist. The samples from two of the three cohorts used in that study were collected between 2001 and 2007, before erythritol was commonly consumed as a sugar substitute. So what accounted for the high erythritol in some people’s blood in the two US-cohorts in which blood samples were drawn before widespread use of erythritol by the US food industry?

It turns out your body makes its own erythritol from glucose through something called the pentose phosphate pathway. And this pathway may be dysregulated and produce more erythritol in people with obesity, insulin resistance, and diabetes: all risk factors for heart disease. In other words, this may be a case of what we call confounding, or confusion of effects: metabolic dysfunction may cause both higher erythritol levels in the blood and higher risk of heart disease – meaning that erythritol is simply a signal and not a cause of disease.

Confounding, or confusion of effects, means that there may be additional variables (obesity and metabolic dysfunction in this case) that are associated with both the exposure of interest (blood erythritol in this case) and also with the endpoint of interest (incident CVD in this case). Whereas the study found that higher blood erythritol was associated with incident CVD, it cannot be fully ruled out that the real factor driving CVD risk is obesity and metabolic dysfunction, which is known to raise blood erythritol levels.
Confounding, or confusion of effects, means that there may be additional variables (obesity and metabolic dysfunction in this case) that are associated with both the exposure of interest (blood erythritol in this case) and also with the endpoint of interest (incident CVD in this case). Whereas the study found that higher blood erythritol was associated with incident CVD, it cannot be fully ruled out that the real factor driving CVD risk is obesity and metabolic dysfunction, which is known to raise blood erythritol levels.

And indeed, the people with the highest blood levels of erythritol in this study had a much higher prevalence of diabetes and heart disease, and they were also more than 10 years older, on average. Researchers tried to statistically adjust for these other risk factors of CVD that also raise blood erythritol levels, but, as we know, some factors such as insulin resistance or visceral fat mass are not being measured in such studies and therefore cannot be adjusted for. Furthermore, the majority of the people in these cohorts already had coronary artery disease and were, therefore, at higher risk for cardiovascular events than the general population. This does not invalidate these findings, but it means they shouldn’t be generalized to younger and healthier populations. So, some questions remain, and from these three observational studies, all we can conclude is that higher blood erythritol is correlated with higher risk of a cardiovascular event, especially among people with pre-existing cardiometabolic conditions, but this does not mean that it causes cardiovascular events.

Because that in and of itself is a weak finding, the same researchers included a small feeding experiment with 8 healthy volunteers who were asked to consume 30 grams of erythritol to see whether dietary erythritol could even lead to the blood concentrations that were associated with heart disease in the observational study. They found that there is a huge spike in blood erythritol following ingestion and that it remains elevated beyond levels associated with heart disease for a couple of days. Normal blood erythritol levels in blood average around 2-8 uM. People with an increased risk of CVD in the aforementioned cohorts had blood erythritol concentrations up to 130 uM, and postprandial concentrations after a single dose can reach 5,000 to 8,000 uM, and remain elevated well above normal for days.

Blood erythritol concentrations in people with a low CVD risk (blue shaded area) vs. high CVD risk (purple shaded area), as well as in eight people before and after drinking 30 g of erythritol in water.
Blood erythritol concentrations in people with a low CVD risk (blue shaded area) vs. high CVD risk (purple shaded area), as well as in eight people before and after drinking 30 g of erythritol in water.

Again, this sounds alarming. But without knowing whether erythritol really causes cardiovascular disease, it’s hard to know whether or not to be concerned about post-prandial rises in erythritol. 

As an analogy, high levels of creatinine in the blood can be used as an indicator of poor kidney function, but eating high amounts of protein can also acutely raise your creatinine without causing damage to your kidneys. Erythritol might similarly be a marker influenced by food and the body’s own metabolic processes, and we just don’t know for sure if it actually causes damage on its own.

Later Studies — Did Additional Research Clear It Up?

So the obvious next move is to design smarter studies that dodge that chicken-and-egg problem. Did later research clear erythritol’s name? 

Not exactly.

Several other studies came out shortly after, suggesting similar findings of worse heart health and increased risk of total mortality among those with higher levels of erythritol in their blood. But they had similar flaws: they did not measure dietary erythritol intake and could not disentangle whether higher blood erythritol caused disease and mortality or was the result of poor metabolic health that causes disease and mortality. For example, one study reported that blood erythritol levels were associated with overall mortality, cardiovascular disease mortality, and cancer mortality in men across the ~19 years of follow-up. Again, however, blood samples were collected in 1985-1993 – way before erythritol was common in the food supply. Another study  with data collected more recently (2011-2013) reported that both erythritol and its downstream metabolite, erythronate, were associated with hospitalization related to heart failure, cardiovascular disease mortality, and total mortality among older adults (>70 years) across the median 8 years of follow-up. They tried to address the issue of confounding by examining if the association differed among those with and without diabetes, and they found no suggestion that it did. Nonetheless, just as in previous studies, people with the highest levels of erythritol had a higher prevalence of diabetes, as well as higher body mass, higher levels of inflammation, higher triglycerides, higher prevalence of hypertension, and worse kidney function. Importantly, none of these studies actually measured dietary intake of erythritol.

Some researchers further tried to address the issue of confounding by looking at genes related to erythritol production. Some people are born with genes linked to higher erythritol production and therefore have higher erythritol in their blood, independent of age or metabolic dysfunction. The idea is that if those genes are also linked to increased risk of heart disease, then we can’t just blame obesity and metabolic dysfunction as being the culprit causing both high erythritol and heart disease. 

Those genetic studies, however, came back mixed. One of the three found no relationship between genes related to erythritol production and coronary artery disease, but this study looked at only a few gene variants. The two other studies looked at a larger number of gene variants and found that genes linked to higher erythritol were associated with greater risk of coronary heart disease and ischemic stroke, but the strength of the associations in one of those was tiny and of questionable clinical relevance – we’re talking about a 0.2% increase in the odds of heart disease in relation to genes related to higher erythritol.

It’s also generally questionable that such genetic studies, we call them Mendelian Randomization studies, can be informative on this particular issue. Take a look again at the normal level of erythritol in the figure above. People who carry genes that keep their erythritol levels low have concentrations in the 2-4 uM range, whereas people with high-erythritol genes have levels in the 4-8 uM range. That’s many-fold lower than the concentrations associated with cardiovascular disease, and thousand-fold lower than what we find in blood after consuming erythritol. 

Then some studies tried to understand the mechanism by which erythritol could lead to disease. In one, researchers gave healthy volunteers either erythritol or glucose, then tested what happened in their blood. The glucose group’s platelets – the little cells that form blood clots – behaved totally normally. The erythritol group’s platelets got stickier, more clot-prone, in the 30 minutes after drinking it.

That’s worth taking seriously. You may have heard that when people have a high risk of a heart attack, they may be prescribed medication to make the blood ‘thinner’. What that essentially means is that the medication lowers the blood’s ability or readiness to form a clot. In these studies, performed in a test tube, erythritol basically made the blood ‘thicker’, that is, more likely to clot.

But here’s the fine print: the researchers had to extract the platelets from the blood and then stimulate them with chemicals to induce the clotting. And while such tests in test tubes are good for detecting defects in the blood-clotting system, it’s less clear whether differences in how readily platelets clot in a test tube translates into more blood clots in a person.  So, again, these experiments are suggestive, but we still don’t really know whether consuming erythritol regularly would actually make blood clots more likely.

Then in 2025 came an even scarier set of headlines suggesting erythritol harms our brain. But here’s the catch: that study was done in a petri dish. Researchers bathed human brain-blood-vessel cells in erythritol and saw more oxidative stress and worse clot-clearing. But remember: cells in a dish are not a person, with many complex cellular processes constantly occurring in response to what enters the body.

In general, the proper way to use such data is not to discard them because they were “just” petri-dish studies. But neither would it be appropriate to treat them like conclusive evidence. The key is to weigh each piece of evidence appropriately; in this case, I’d say all of these data are modestly suggestive that erythritol may be harmful. Unfortunately, we cannot say anything more conclusive.

What Kind of Evidence Do We Need?

So what would truly settle this? Long-term, well-controlled human trials where you randomize people to consume or not consume erythritol regularly, track their real health over years, and compare the health outcomes of those who ate erythritol to those who did not. We don’t have those kinds of studies.

A randomized controlled trial of erythritol vs. a no-erythritol control, with long-term follow up and hard disease endpoints, is what would be needed to conclusively answer the question whether dietary erythritol indeed raises CVD risk.
A randomized controlled trial of erythritol vs. a no-erythritol control, with long-term follow up and hard disease endpoints, is what would be needed to conclusively answer the question whether dietary erythritol indeed raises CVD risk.

Now that erythritol is on the market in many countries, we will also get observational data from cohorts in which some people consume lots of erythritol and others none, and that may provide more insight into whether DIETARY erythritol intake is actually associated with a higher risk of cardiovascular events.

Currently, the longest human trial looking at heart and metabolic health is a 5-week pilot study conducted among adults with obesity, comparing the effects of 36 grams/day of erythritol to 24 grams/day of xylitol or nothing. It had only 14 people per group, and measured only markers of disease risk – not actual disease outcomes. It found no harm from 36 grams of erythritol per day to measures of vascular function used as early markers of cardiovascular disease. Notably, however, the researchers did not assess the impact of erythritol on blood clotting, the specific mechanism suspected to link erythritol to higher CVD risk. The study also found no benefits for visceral or liver fat, glucose tolerance, or blood lipids compared with the control group. However, the study didn’t ask participants to replace sugar with erythritol (they just added it to their normal diets), and all groups happened to reduce their intake of sugar-sweetened beverages. These factors may have influenced the ability to observe differences between the three groups. In summary, adding daily consumption of erythritol seemed to have neutral effects for people with obesity, but with such a small study sample size, short duration, and use of erythritol as an additive instead of a replacement for sugar, it is really hard to say from this study what the long-term impacts are and what the impacts would be of replacing sugar with erythritol for either healthy people or people with pre-existing conditions.

So ... Should You Worry?

Here’s the bottom line. Erythritol has real perks: it’s sweet and doesn’t have a bitter aftertaste, it’s essentially calorie-free, it doesn’t cause cavities, and it won’t spike your blood sugar. So it would THEORETICALLY be a great substitute for sugar.

What it does NOT have is any proof it helps people lose weight or improve their metabolic health, and it DOES have a growing pile of question marks around heart health, especially among people whose health is already compromised. None of these pieces of evidence are perfect, so we also cannot say for sure that erythritol is problematic. In short, erythritol is not proven to be harmful, but also not proven to be safe.

The perks of and questions around dietary erythritol at this time.
The perks of and questions around dietary erythritol at this time.

So where does that leave you? It really comes down to your general approach to risk: do you assume a new food ingredient is going to be just fine until we have proof that it is unhealthy? Or do you adhere to the precautionary principle and assume that a new food ingredient is unhealthy until proven otherwise? I am a proponent of the precautionary principle, and even though the available evidence has some very big holes, I will avoid regular consumption of larger quantities of erythritol, for now, until we have better evidence.

The available data that erythritol may make blood ‘thicker’, that is, make blood more likely to clot, would suggest that avoiding erythritol is particularly important for people with a high risk for cardiovascular disease, or who have had a cardiovascular event before. 

However, I certainly don’t think you need to panic if you eat something with erythritol now and then. My best guess is that occasional small amounts won’t meaningfully affect risk if you don’t have an overall elevated CVD risk.

And zooming out for a second: where do we actually run into big doses of erythritol? Ultra-processed foods, such as ice cream, cookies, protein bars, zero-sugar energy drinks. These are all foods we should probably be limiting anyway. So this comes back to the advice I always give: eat mostly whole, unprocessed, or minimally processed food, and avoid ultra-processed foods. This means treating even the so-called “natural” sweeteners as an only “sometimes” thing, at most.

A big thank you goes to Dr. Hilary Bethancourt, a very talented researcher who recently joined the team and who did much of the legwork on this blog post and the associated YouTube video. This was her first project, so feel free to welcome her and let her know in the comments if you liked it.

Also consider supporting our work through a one-time donation or regularly through Patreon. It is our goal to continue to make this content freely available, and to do so in a way that is free of financial conflicts of interest. We therefore do not engage in any relationship with interests in the food, pharmaceutical, or supplement industries.

Thank you, and take care.

References

  1. Moriconi E, Feraco A, Marzolla V, Infante M, Lombardo M, Fabbri A, Caprio M. Neuroendocrine and Metabolic Effects of Low-Calorie and Non-Calorie Sweeteners. Front Endocrinol (Lausanne). 2020 Jul 16;11:444. doi: 10.3389/fendo.2020.00444. PMID: 32765425; PMCID: PMC7378387.
  2. Meyer-Gerspach AC, Wingrove JO, Beglinger C, Rehfeld JF, Le Roux CW, Peterli R, Dupont P, O’Daly O, Van Oudenhove L, Wölnerhanssen BK. Erythritol and xylitol differentially impact brain networks involved in appetite regulation in healthy volunteers. Nutr Neurosci. 2022 Nov;25(11):2344-2358. doi: 10.1080/1028415X.2021.1965787. Epub 2021 Aug 18. PMID: 34404339.
  3. Wölnerhanssen BK, Cajacob L, Keller N, Doody A, Rehfeld JF, Drewe J, Peterli R, Beglinger C, Meyer-Gerspach AC. Gut hormone secretion, gastric emptying, and glycemic responses to erythritol and xylitol in lean and obese subjects. Am J Physiol Endocrinol Metab. 2016 Jun 1;310(11):E1053-61. doi: 10.1152/ajpendo.00037.2016. Epub 2016 Apr 26. PMID: 27117004.
  4. Storey D, Lee A, Bornet F, Brouns F. Gastrointestinal tolerance of erythritol and xylitol ingested in a liquid. Eur J Clin Nutr. 2007 Mar;61(3):349-54. doi: 10.1038/sj.ejcn.1602532. Epub 2006 Sep 20. PMID: 16988647.
  5. Sreenath K, Venkatesh YP. Analysis of erythritol in foods by polyclonal antibody-based indirect competitive ELISA. Anal Bioanal Chem. 2008 May;391(2):609-15. doi: 10.1007/s00216-008-2016-x. Epub 2008 Mar 28. PMID: 18369603.
  6. EFSA FAF Panel (EFSA Panel on Food Additives and Flavourings), Younes, M., Aquilina, G., Castle, L., Degen, G., Engel, K.-H., Fowler, P. J., Frutos Fernandez, M. J., Fürst, P., Gundert-Remy, U., Gürtler, R., Husøy, T., Manco, M., Mennes, W., Moldeus, P., Passamonti, S., Shah, R., Waalkens-Berendsen, I., Wright, M. … Tard, A. (2023). Re-evaluation of erythritol (E 968) as a food additive. EFSA Journal, 21(12), e8430. https://doi.org/10.2903/j.efsa.2023.8430
  7. Oku T, Okazaki M. Laxative threshold of sugar alcohol erythritol in human subjects. Nutrition Research. 1996 Apr 1;16(4):577-89.
  8. US Food and Drug Administration GRAS notice 76: Erythritol. [(accessed on 14 October 2026)];2001 Available online: https://www.cfsanappsexternal.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices&id=76&sort=GRN_No&order=DESC&startrow=1&type=basic&search=erythritol.
  9. European Commission-Health & Consumer Protection Directorate. Opinion of the Scientific Committee on Food on Erythritol. 2003. [(accessed on 14 October 2026)]. Available online: https://ec.europa.eu/food/system/files/2020-12/sci-com_scf_out175_en.pdf.
  10. den Hartog GJ, Boots AW, Adam-Perrot A, Brouns F, Verkooijen IW, Weseler AR, Haenen GR, Bast A. Erythritol is a sweet antioxidant. Nutrition. 2010 Apr;26(4):449-58. doi: 10.1016/j.nut.2009.05.004. Epub 2009 Jul 24. PMID: 19632091.
  11. Boesten DM, Berger A, de Cock P, Dong H, Hammock BD, den Hartog GJ, Bast A. Multi-targeted mechanisms underlying the endothelial protective effects of the diabetic-safe sweetener erythritol. PLoS One. 2013 Jun 5;8(6):e65741. doi: 10.1371/journal.pone.0065741. PMID: 23755276; PMCID: PMC3673924.
  12. Flint N, Hamburg NM, Holbrook M, Dorsey PG, LeLeiko RM, Berger A, de Cock P, Bosscher D, Vita JA. Effects of erythritol on endothelial function in patients with type 2 diabetes mellitus: a pilot study. Acta Diabetol. 2014;51(3):513-6. doi: 10.1007/s00592-013-0534-2. Epub 2013 Dec 24. PMID: 24366423; PMCID: PMC4037362.
  13. Wölnerhanssen BK, Cajacob L, Keller N, Doody A, Rehfeld JF, Drewe J, Peterli R, Beglinger C, Meyer-Gerspach AC. Gut hormone secretion, gastric emptying, and glycemic responses to erythritol and xylitol in lean and obese subjects. Am J Physiol Endocrinol Metab. 2016 Jun 1;310(11):E1053-61. doi: 10.1152/ajpendo.00037.2016. Epub 2016 Apr 26. PMID: 27117004.
  14. Teysseire F, Bordier V, Budzinska A, Weltens N, Rehfeld JF, Holst JJ, Hartmann B, Beglinger C, Van Oudenhove L, Wölnerhanssen BK, Meyer-Gerspach AC. The Role of D-allulose and Erythritol on the Activity of the Gut Sweet Taste Receptor and Gastrointestinal Satiation Hormone Release in Humans: A Randomized, Controlled Trial. J Nutr. 2022 May 5;152(5):1228-1238. doi: 10.1093/jn/nxac026. PMID: 35135006; PMCID: PMC9071322.
  15. Meyer-Gerspach AC, Wingrove JO, Beglinger C, Rehfeld JF, Le Roux CW, Peterli R, Dupont P, O’Daly O, Van Oudenhove L, Wölnerhanssen BK. Erythritol and xylitol differentially impact brain networks involved in appetite regulation in healthy volunteers. Nutr Neurosci. 2022 Nov;25(11):2344-2358. doi: 10.1080/1028415X.2021.1965787. Epub 2021 Aug 18. PMID: 34404339.
  16. Teysseire F, Flad E, Bordier V, Budzinska A, Weltens N, Rehfeld JF, Beglinger C, Van Oudenhove L, Wölnerhanssen BK, Meyer-Gerspach AC. Oral Erythritol Reduces Energy Intake during a Subsequent ad libitum Test Meal: A Randomized, Controlled, Crossover Trial in Healthy Humans. Nutrients. 2022 Sep 21;14(19):3918. doi: 10.3390/nu14193918. PMID: 36235571; PMCID: PMC9571225.
  17. Witkowski M, Nemet I, Alamri H, Wilcox J, Gupta N, Nimer N, Haghikia A, Li XS, Wu Y, Saha PP, Demuth I, König M, Steinhagen-Thiessen E, Cajka T, Fiehn O, Landmesser U, Tang WHW, Hazen SL. The artificial sweetener erythritol and cardiovascular event risk. Nat Med. 2023 Mar;29(3):710-718. doi: 10.1038/s41591-023-02223-9. Epub 2023 Feb 27. PMID: 36849732; PMCID: PMC10334259.
  18. Mazi TA, Stanhope KL. Erythritol: An In-Depth Discussion of Its Potential to Be a Beneficial Dietary Component. Nutrients. 2023 Jan 1;15(1):204. doi: 10.3390/nu15010204. PMID: 36615861; PMCID: PMC9824470.
  19. Ge T, Yang J, Zhou S, Wang Y, Li Y, Tong X. The Role of the Pentose Phosphate Pathway in Diabetes and Cancer. Front Endocrinol (Lausanne). 2020 Jun 9;11:365. doi: 10.3389/fendo.2020.00365. PMID: 32582032; PMCID: PMC7296058. 
  20. Lim J, Hong HG, Huang J, Stolzenberg-Solomon R, Mondul AM, Weinstein SJ, Albanes D. Serum Erythritol and Risk of Overall and Cause-Specific Mortality in a Cohort of Men. Nutrients. 2024 Sep 14;16(18):3099. doi: 10.3390/nu16183099. PMID: 39339699; PMCID: PMC11434845.
  21. Abushamat LA, Yu B, Hoogeveen RC, Sun C, Cheng C, Hartig SM, Herman MA, Balasubramanyam A, Reusch JE, Selvin E, Ndumele CE, Nambi V, Ballantyne CM. Erythritol, Erythronate, and Cardiovascular Outcomes in Older Adults in the ARIC Study. JACC Adv. 2025 Mar;4(3):101605. doi: 10.1016/j.jacadv.2025.101605. Epub 2025 Feb 20. PMID: 39983608; PMCID: PMC11889355.
  22. Khafagy R, Paterson AD, Dash S. Erythritol as a Potential Causal Contributor to Cardiometabolic Disease: A Mendelian Randomization Study. Diabetes. 2024 Feb 1;73(2):325-331. doi: 10.2337/db23-0330. PMID: 37939167.
  23. Sun Y, Sun D, Wu J, Peng Z, Jin J. Role of erythritol in coronary heart disease, ischemic stroke, and venous thromboembolism: A Mendelian randomization analysis. Medicine (Baltimore). 2025 Oct 24;104(43):e45187. doi: 10.1097/MD.0000000000045187. PMID: 41137360; PMCID: PMC12558269.
  24. Fan J, Hu Y, Zhang J, Chen J, Yuan Y, Yu B. Associations between artificial sweeteners and cardiovascular disease, stroke, and diabetes: A Mendelian randomization study. Am J Prev Cardiol. 2025 Oct 6;24:101325. doi: 10.1016/j.ajpc.2025.101325. PMID: 41141604; PMCID: PMC12547948.
  25. Witkowski M, Wilcox J, Province V, Wang Z, Nemet I, Tang WHW, Hazen SL. Ingestion of the Non-Nutritive Sweetener Erythritol, but Not Glucose, Enhances Platelet Reactivity and Thrombosis Potential in Healthy Volunteers-Brief Report. Arterioscler Thromb Vasc Biol. 2024 Sep;44(9):2136-2141. doi: 10.1161/ATVBAHA.124.321019. Epub 2024 Aug 8. PMID: 39114916; PMCID: PMC11338701.
  26. Berry AR, Ruzzene ST, Ostrander EI, Wegerson KN, Orozco-Fersiva NC, Stone MF, Valenti WB, Izaias JE, Holzer JP, Greiner JJ, Garcia VP, DeSouza CA. The non-nutritive sweetener erythritol adversely affects brain microvascular endothelial cell function. J Appl Physiol (1985). 2025 Jun 1;138(6):1571-1577. doi: 10.1152/japplphysiol.00276.2025. Epub 2025 Jun 3. PMID: 40459966.
  27. Bordier V, Teysseire F, Drewe J, Madörin P, Bieri O, Schmidt-Trucksäss A, Hanssen H, Beglinger C, Meyer-Gerspach AC, Wölnerhanssen BK. Effects of a 5-week intake of erythritol and xylitol on vascular function, abdominal fat and glucose tolerance in humans with obesity: a pilot trial. BMJ Nutr Prev Health. 2023 Nov 14;6(2):264-272. doi: 10.1136/bmjnph-2023-000764. PMID: 38618550; PMCID: PMC11009538.

Leave a Comment